liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Expression and clinical significance of FXYD3 in endometrial cancer
First Hospital of Hebei Medical University, Shijiazhuang, China.
First Hospital of Hebei Medical University, Shijiazhuang, China.
First Hospital of Hebei Medical University, Shijiazhuang, China.
First Hospital of Hebei Medical University, Shijiazhuang, China.
Show others and affiliations
2014 (English)In: Oncology Letters, ISSN 1792-1074, E-ISSN 1792-1082, Vol. 8, no 2, 517-522 p.Article in journal (Refereed) Published
Abstract [en]

FXYD3 expression is upregulated in numerous cancer cell types. The present study compared the FXDY3 expression in normal endometrium, premalignant lesion and endometrial cancer tissue samples, and investigated the correlation between FXDY3 expression and clinicopathological features. FXYD3 expression was analyzed by streptavidin-peroxidase immunohistochemistry in 21 normal endometrial tissue samples, 18 atypical endometrial hyperplasia samples and 50 tissues obtained from patients diagnosed with endometrial cancer. The percentage of FXYD3-positive cell expression in the normal endometrium, atypical hyperplasia and endometrial cancer tissues samples was 0, 22, and 26%, respectively. The differences between the atypical hyperplasia and endometrial cancer groups were statistically significant when compared with the normal group (P=0.007 and P=0.037, respectively). There was no significant difference between the atypical hyperplasia and endometrial cancer groups. The percentage of FXYD3-positive cells correlated with the fertility frequency (Pless than0.05). In conclusion, FXYD3 is a potential biomarker for endometrial cancer, and its upregulation may be an early event in endometrial carcinoma progression. In addition, FXYD3 expression in endometrial carcinoma correlates with fertility frequency.

Place, publisher, year, edition, pages
Spandidos Publications , 2014. Vol. 8, no 2, 517-522 p.
Keyword [en]
FXYD3; endometrial hyperplasia; endometrial neoplasm; immunohistochemistry
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:liu:diva-109366DOI: 10.3892/ol.2014.2170ISI: 000339127300007OAI: oai:DiVA.org:liu-109366DiVA: diva2:738073
Available from: 2014-08-15 Created: 2014-08-15 Last updated: 2017-12-05Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Authority records BETA

Sun, Xiao-Feng

Search in DiVA

By author/editor
Sun, Xiao-Feng
By organisation
Division of Clinical SciencesFaculty of Health SciencesDepartment of Oncology
In the same journal
Oncology Letters
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 110 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf